Biopharma News

Sanofi says it would buy all of the outstanding shares of Principia for $100 per share in cash, representing an aggregate equity value of approximately $3.68 billion on a fully diluted basis

Strides Pharma in September announced that it would invest an additional $40 million over a five year period for a controlling stake in biopharmaceutical firm Stelis Biopharma Pvt LtdStelis Biopharma is in the business of biopharmaceuticals, contract manufacturing and biologics research services

The founder of Sino Biopharmaceutical Ltd. and his wife are transferring about a fifth of the company’s share capital to their son Eric Tse, making him one of the world’s richest people overnight

The investment commitment would span across AstraZeneca's diverse footprint in India with an aim to strengthen its manufacturing, clinical operations, patient safety regulatory science, IT services and commercial operations

The acquisition deal between Aurobindo Pharma and Shreya Life Sciences for the latter's Russia business is potentially valued at $80 milllion to $100 million

The current draft pharma policy may have a negative impact on growth and profitability of the industry due to continued emphasis on price control, say industry officials and analysts

Samsung BioLogics is building a $740 million factory that will give it the capacity to become the No. 1 producer by volume of a class of drugs called biologics

TL Biopharmaceutical will supply all the developmental data for four molecules and Aurobindo Pharma or its affiliates will develop, commercialize and market the products globally

Despite raising list prices, big pharma's have been unable to boost revenue, thanks to steep discounts and flat prescriptions

The acquisition will significantly boost market share of Advanced Enzyme Tech in the enzymes space and enable it to enter the biopharmaceutical molecules space